Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: The utility of IFNγ assay

Annals of the Rheumatic Diseases

Volumn 71, Issue 2, 2012, Pages 231-237

  Chen, Der Yuan ^a,b,c,d   Shen, Gwan Han ^c,e   Chen, Yi Ming ^a,b,c   Chen, Hsin Hua ^a,b,c   Hsieh, Chia Wei ^a,b,c,d   Lan, Joung Liang ^a,b,c,d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GAMMA INTERFERON; HYDROXYCHLOROQUINE; ISONIAZID; METHOTREXATE; PREDNISOLONE; RIFAMPICIN; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; FEMALE; HUMAN; INJECTION SITE INDURATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NONPARAMETRIC TEST; PRIORITY JOURNAL; PROPHYLAXIS; RHEUMATOID ARTHRITIS; SPUTUM SMEAR; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULIN G; INTERFERON-GAMMA; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; TUBERCULIN TEST; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84855413540     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200489     Document Type: Article

References (50)

1. Hsueh P R, Liu YC, So J, et al. Mycobacterium tuberculosis in Taiwan. J Infect 2006;52:77-85. (Pubitemid 43137388)
2. Centers for Disease Control. Statistics of Communicable Disease and Surveillance Report in Taiwan Area, 2007. Taipei: Centers for Disease Control, 2009.
3. Carmona L, Hernández-García C, Vadillo C, et al. I ncreased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003;30:1436-9. (Pubitemid 36835436)
4. Gómez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7.
5. Gardam M A, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148-55. (Pubitemid 36278124)
6. Furst D E, Cush J, Kaufmann S, et al. Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Ann Rheum Dis 2002;61(Suppl 2):ii62-3.
7. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52:1766-72. (Pubitemid 40852885)
8. Porsa E, Cheng L, Seale MM, et al. C omparison of a new ESAT-6/CFP-10 peptidebased gamma interferon assay and a tuberculin skin test for tuberculosis screening in a moderate-risk population. Clin Vaccine Immunol 2006;13:53-8.
9. Brock I, Weldingh K, Lillebaek T, et al. C omparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 2004;170:65-9. (Pubitemid 38997753)
10. Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A, et al. . Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005;64:1360-1. (Pubitemid 41206259)
11. Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 2004;170:59-64. (Pubitemid 38997752)
12. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008;149:177-84.
13. Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. Chest 2010;137:952-68.
14. Pratt A, Nicholl K, Kay L. Use of the QuantiFERON TB Gold test as part of a screening programme in patients with RA under consideration for treatment with anti-TNF-alpha agents: the Newcastle (UK) experience. Rheumatology (Oxford) 2007;46:1035- 6.
15. Sellam J, Hamdi H, Roy C, et al. C omparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis 2007;66:1610-15. (Pubitemid 350205449)
16. Chen D Y, Shen GH, Hsieh TY, et al. E ffectiveness of the combination of a wholeblood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 2008;59:800-6.
17. Martin J, Walsh C, Gibbs A, et al. Comparison of interferon {gamma} release assays and conventional screening tests before tumour necrosis factor {alpha} blockade in patients with inflammatory arthritis. Ann Rheum Dis 2010;69:181-5.
18. Matulis G, Jüni P, Villiger PM, et al. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis 2008;67:84-90.
19. Luetkemeyer A F, Charlebois ED, Flores LL, et al. Comparison of an interferongamma release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med 2007;175:737-42. (Pubitemid 46536491)
20. Mazurek G H, Jereb J, Vernon A, et al. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Recomm Rep 2010;59(RR-5):1-25.
21. Diel R, Loddenkemper R, Meywald-Walter K, et al. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis . Am J Respir Crit Care Med 2008;177:1164-70. (Pubitemid 351717577)
22. Arnett F C, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
23. Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 2005;44:157-63. (Pubitemid 40277395)
24. Prevoo M L, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
25. American Thoracic Society. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000; 161 :1376-95.
26. Pai M, Joshi R, Dogra S, et al. Serial testing of health care workers for tuberculosis using interferon-gamma assay. Am J Respir Crit Care Med 2006;174:349-55. (Pubitemid 44156616)
27. Kobashi Y, Obase Y, Fukuda M, et al. Clinical reevaluation of the QuantiFERON TB-2G test as a diagnostic method for differentiating active tuberculosis from nontuberculous mycobacteriosis. Clin Infect Dis 2006;43:1540-6. (Pubitemid 44901894)
28. Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A, et al. . Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005;64:1360-1. (Pubitemid 41206259)
29. Huebner R E, Schein MF, Bass JB Jr. The tuberculin skin test. C lin Infect Dis 1993;17:968-75. (Pubitemid 23358739)
30. Casas I, Latorre I, Esteve M, et al. Evaluation of interferon-gamma release assays in the diagnosis of recent tuberculosis infection in health care workers. PLoS ONE 2009;4:e6686.
31. B artalesi F, Vicidomini S, Goletti D, et al. Q uantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J 2009;33:586-93.
32. D ing L W, Lai CC, Lee LN, et al. D isease caused by non-tuberculous mycobacteria in a university hospital in Taiwan, 1997-2003. Epidemiol Infect 2006;134:1060-7.
33. Kunimoto D, Der E, Beckon A, et al. Use of the QuantiFERON-TB Gold test to confirm latent tuberculosis infection in a Canadian tuberculosis clinic. Int J Tuberc Lung Dis 2009;13:726-30.
34. Hardy A B, Varma R, Collyns T, et al. Cost-effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the QuantiFERON-TB Gold IGRA alone is more cost-effective for immigrants from high burden countries. Thorax 2010;65:178-80.
35. Pooran A, Booth H, Miller RF, et al. Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis. BMC Pulm Med 2010;10:7.
36. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935-52. (Pubitemid 44564795)
37. Vanhoof J, Landewe S, Van Wijngaerden E, et al. High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors. Ann Rheum Dis 2003;62:1241-2. (Pubitemid 37500639)
38. Mazurek G H, Weis SE, Moonan PK, et al. Prospective comparison of the tuberculin skin test and 2 whole-blood interferon-gamma release assays in persons with suspected tuberculosis. Clin Infect Dis 2007;45:837-45. (Pubitemid 47580374)
39. Higuchi K, Harada N, Mori T. Interferon-gamma responses after isoniazid chemotherapy for latent tuberculosis. Respirology 2008;13:468-72. (Pubitemid 351503140)
40. Hamdi H, Mariette X, Godot V, et al. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 2006;8:R114.
41. Hill P C, Fox A, Jeffries DJ, et al. Q uantitative T cell assay reflects infectious load of Mycobacterium tuberculosis in an endemic case contact model. Clin Infect Dis 2005;40:273-8. (Pubitemid 40110673)
42. Sichletidis L, Settas L, Spyratos D, et al. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006;10:1127-32. (Pubitemid 44519351)
43. Girling DJ, Chan SL. A double-blind placebo-controlled trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Resp Dis 1992;145:36-41.
44. Bright-Thomas R, Nandwani S, Smith J, et al. Effectiveness of 3 months of rifampicin and isoniazid chemoprophylaxis for the treatment of latent tuberculosis infection in children. Arch Dis Child 2010;95:600-2.
45. Dosanjh D P, Hinks TS, Innes JA, et al. Improved diagnostic evaluation of suspected tuberculosis. Ann Intern Med 2008;148:325-36. (Pubitemid 351665463)
46. Goletti D, Carrara S, Stefania C, et al. Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: a multicenter TBNET-Study. PLoS ONE 2008;3:e3417.
47. Andersen P, Doherty TM, Pai M, et al. The prognosis of latent tuberculosis: can disease be predicted? Trends Mol Med 2007;13:175-82. (Pubitemid 46687128)
48. Doherty T M, Demissie A, Olobo J, et al. Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J Clin Microbiol 2002;40:704-6. (Pubitemid 34130912)
49. Kobashi Y, Mouri K, Yagi S, et al. Clinical utility of a T cell-based assay in the diagnosis of extrapulmonary tuberculosis. Respirology 2009;14:276-81.
50. Kobashi Y, Mouri K, Yagi S, et al. Clinical evaluation for diagnosing active TB disease and transitional change of two commercial blood tests. Scand J Infect Dis 2008;40:629-34.